Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Jan 24, 2023

BUY
$285.76 - $321.48 $534,656 - $601,489
1,871 Added 75.9%
4,336 $0
Q3 2022

Nov 03, 2022

BUY
$273.83 - $305.53 $674,990 - $753,131
2,465 New
2,465 $714,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $55,872 - $65,887
-298 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$207.02 - $241.31 $2,484 - $2,895
-12 Reduced 3.87%
298 $64,000
Q4 2020

Feb 18, 2021

SELL
$207.01 - $276.09 $4,554 - $6,073
-22 Reduced 6.63%
310 $73,000
Q3 2020

Nov 16, 2020

BUY
$255.65 - $303.1 $15,594 - $18,489
61 Added 22.51%
332 $90,000
Q2 2020

Aug 14, 2020

SELL
$225.48 - $295.8 $18,714 - $24,551
-83 Reduced 23.45%
271 $79,000
Q1 2020

May 05, 2020

BUY
$199.77 - $247.81 $7,990 - $9,912
40 Added 12.74%
354 $84,000
Q4 2019

May 05, 2020

BUY
$166.71 - $223.91 $52,346 - $70,307
314 New
314 $69,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Eudaimonia Partners, LLC Portfolio

Follow Eudaimonia Partners, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eudaimonia Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eudaimonia Partners, LLC with notifications on news.